Results 1 to 10 of about 72,827 (181)

Prevalence of potentially inappropriate use of antiviral therapy with simnotrelvir-ritonavir versus nirmatrelvir-ritonavir in hospitalised patients: a retrospective study in Beijing, China [PDF]

BMJ Open Respiratory Research
Background While simnotrelvir-ritonavir and nirmatrelvir-ritonavir, the oral antiviral agents targeting the 3C-like proteases, are widely used in China, robust data on their appropriate use remain limited in hospitalised patients.
Hui Zhang, Hui Yang, Yi Zhang, Jia Li, Han Wu, Xintong Zhang, Zhuoling An, Yuezhen Zhu, Chunguo Jiang, Wanying Chen   +9 more
doaj   +2 more sources

A case report of drug–drug interaction between voriconazole and simnotrelvir/ritonavir [PDF]

Frontiers in Antibiotics
Co-administration of simnotrelvir/ritonavir with voriconazole should be avoided, as stated in the product insert of simnotrelvir/ritonavir, due to the anticipated decrease in the plasma concentration of voriconazole.
Tingting Chen, Qingquan Zhang
doaj   +2 more sources

Nirmatrelvir/Ritonavir Utilization for the Treatment of Non-hospitalized Adults with COVID-19 in the National Veterans Affairs (VA) Healthcare System

Infectious Diseases and Therapy
Introduction Limited data exist regarding real-world utilization of nirmatrelvir/ritonavir. We identified predictors of nirmatrelvir/ritonavir use among Veterans Affairs (VA) outpatients nationally. Methods We conducted a retrospective cohort study among
Kerry L Laplante, Catherine Martin, Aisling R Caffrey   +2 more
exaly   +2 more sources

Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial [PDF]

, 2017
Objectives Primary study outcome was absence of treatment failure (virological failure, VF, or treatment interruption) per protocol at week 48.
Antinori, Andrea, Biagio, Antonio Di, Canovari, Benedetta, Colafigli, Manuela, Colangeli, Vincenzo, De Luca, Andrea, D’Arminio Monforte, Antonella, D’Avino, Alessandro, Fantauzzi, Alessandra, Francisci, Daniela, Gagliardini, Roberta, Ghisetti, Valeria, Giambenedetto, Simona Di, Grima, Pierfrancesco, Lamonica, Silvia, Latini, Alessandra, Lisi, Lucia, Mastroianni, Claudio, Meini, Genny, Micheli, Valeria, Navarra, Pierluigi, Orofino, Giancarlo, Re, Maria Carla, Rossetti, Barbara, Rusconi, Stefano, Sterrantino, Gaetana, Trezzi, Michele, Vignale, Francesca, Vullo, Vincenzo, Zazzi, Maurizio   +29 more
core   +24 more sources

High Dose Lopinavir/Ritonavir Does Not Lead to Sufficient Plasma Levels to Inhibit SARS-CoV-2 in Hospitalized Patients With COVID-19

Frontiers in Pharmacology, 2021
Background: Despite lopinavir/ritonavir (LPV/RTV) demonstrating in-vitro activity against SARS-CoV-2, large trials failed to show any net clinical benefit. Since SARS-CoV-2 has an EC50 of 16.4 μg/ml for LPV this could be due to inadequate dosing.Methods:
Mario Karolyi, Sara Omid, Erich Pawelka, Bernd Jilma, Thomas Stimpfl, Christian Schoergenhofer, Hermann Laferl, Tamara Seitz, Marianna Traugott, Christoph Wenisch, Alexander Zoufaly   +10 more
doaj   +1 more source

Individuals at risk for severe COVID-19 in whom ritonavir-containing therapies are contraindicated or may lead to interactions with concomitant medications: a retrospective analysis of German health insurance claims data

Drugs in Context, 2023
Background: Nirmatrelvir/ritonavir is authorized for the treatment of COVID-19 but has several contraindications and potential drug–drug interactions (pDDIs) due to ritonavir-induced irreversible inhibition of cytochrome P450 3A4.
Christoph Lübbert, Igor Dykukha, Jann-Patrick Pelz, Helen Yearley, Wolfgang Junker, Nina Gruber, Sibyll Escher, Katrin Biereth, Sima Melnik, Julia Puschmann   +9 more
doaj   +1 more source

Efficacy and safety of narlaprevir/ritonavir and daclatasvir non interferon combination in population of Russian patients with chronic hepatitis C [PDF]

Терапевтический архив, 2019
Aim. Evaluate efficacy and safety of a combination of direct - acting antivirals narlaprevir/ritonavir with daclatasvir in patients with viral hepatitis C. Materials and methods.
E A Klimova, E Z Burnevich, V P Chulanov, D A Gusev, O O Znoyko, S N Batskikh, S N Kizlo, N A Mamonova, E P Tarkhova, E N Krasavina, M Yu Samsonov, N D Yushchuk   +11 more
doaj   +1 more source

Torsade de pointes associated with long-term antiretroviral drugs in a patient with HIV: a case report

Frontiers in Pharmacology, 2023
With the improving life expectancy of patients with human immunodeficiency virus (HIV), there is an increasing health concern of potential toxicity and drug interactions of long-term antiretroviral therapies.
Xuechun Mu, Yujiao Duan, Qiuhua Xu, Sa Wang, Guiju Gao, Ning Han, Hongxin Zhao   +6 more
doaj   +1 more source

Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting. [PDF]

, 2011
In resource-limited settings, many patients, with no prior protease inhibitor (PI) treatment on a second-line, high genetic barrier, ritonavir-boosted PI-containing regimen have virologic ...
Arribas, Bangsberg, Barreiro, Berg, Carolina Malavazzi, Cassani, Delaugerre, El-Khatib, Eric Decloedt, Frost, Gandhi, Gardner, Gary Maartens, Gathe, Gert Uves van Zyl, Helen McIlleron, Huang, Jean B Nachega, Kosuge, Lize van der Merwe, Michele Zeier, Mo, Monica Gandhi, Peter Smith, Pujades-Rodriguez, Quiros-Roldan, Riddler, Thijs E van Mens, van Zyl, van Zyl, Yong Huang   +30 more
core   +6 more sources

Mild self-declared side effects of boosted darunavir associated with other antiretrovirals in Romanian HIV-1 infected patients [PDF]

Archives of the Balkan Medical Union, 2021
Introduction. Antiretroviral therapy (ART) is used in human immunodeficiency virus (HIV)-infected patients, to suppress viral replication and slow disease progression.
Ruxandra C. MARIN, Adrian STREINU-CERCEL, Simona BUNGAU   +2 more
doaj   +1 more source